425.453.0404

US FDA Approved Trials For Schizophrenia

Schizophrenia

GZMK: A Phase 2 Multicenter, Double-Blind, Parallel-Arm Study to Investigate the Efficacy and Safety of Adjunctive Treatment with Brenipatide in Adult Participants with Schizophrenia (RENEWScz-1) (ENROLLING)

NCT07410507

LB-102-010: A 52-Week, Open-label Safety and Tolerability Study of LB-102 in Adult Patients with Schizophrenia (ENROLLING)

NCT07369154

NBI-1117568-SCZ3031: A Phase 3, Multicenter, Double-Blind, PlaceboControlled, Randomized Withdrawal Study to Assess the Efficacy of NBI-1117568 in Preventing Relapse of the Symptoms of Schizophrenia and to Assess the Safety and Tolerability of NBI-1117568 in Adults With Schizophrenia (ENROLLING)

NCT07227818

NBI-1117568-SCZ3032: A Global, Phase 3, Multicenter, Open-Label Study to Assess the Long-Term Safety and Tolerability of NBI-1117568 in Adults with Schizophrenia (ENROLLING)


NCT07114874

Study Evaluation Process

  • Screening: Determine eligibility and safety through medical examinations, questionnaires, and interviews.
  • Informed Consent: Receive detailed information about the trial, including risks and benefits.
  • Treatment: Receive investigational medication and placebo, and follow the trail protocol regarding current treatments and medications.
  • Monitoring: Close monitoring of conditions and side effects through check-ups, laboratory tests, EKG’s and assessments.

NWCRC in Bellevue, WA. Research and medical studies patient lounge.

CONTACT US

To be contacted about this study, fill out the contact form or call 425-453-0404.

This field is for validation purposes and should be left unchanged.
We complete all visits in person. Do you live within 50 miles of Bellevue, WA?(Required)


Are you interested in participating in clinical trials?(Required)


Please indicated which study you are interested in.(Required)